Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123861 | 1.00 | FDFT1 (0.37) | FDFT1ALDH1A1MAPTNR1H4NFE2L2 | |
| SCHEMBL13775240 | 0.93 | FDFT1 (0.39) | FDFT1ALDH1A1MAPTNR1H4NFE2L2 | |
| SCHEMBL4110617 | 0.92 | FDFT1 (0.39) | FDFT1ALDH1A1MAPTKDM4E | |
| SCHEMBL4110619 | 0.92 | FDFT1 (0.39) | FDFT1ALDH1A1MAPTKDM4E | |
| SCHEMBL13775445 | 0.90 | GAA (0.40) | FDFT1ALDH1A1MAPTNR1H4KDM4E | |
| SCHEMBL13775457 | 0.89 | NR1H4 (0.36) | ALDH1A1NR1H4NFE2L2KDM4E | |
| SCHEMBL13775454 | 0.87 | KDM4E (0.34) | FDFT1ALDH1A1MAPTNR1H4KDM4E | |
| SCHEMBL4112300 | 0.85 | FDFT1 (0.41) | FDFT1ALDH1A1MAPTNFE2L2KDM4E | |
| SCHEMBL4112306 | 0.85 | FDFT1 (0.41) | FDFT1ALDH1A1MAPTNFE2L2KDM4E | |
| SCHEMBL4118309 | 0.84 | FFAR4 (0.38) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | FDFT1 1/4885ALDH1A1 1587/4885MAPT 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.